CClinicalTrials.gg
CompletedNCT06275880Updated Feb 23, 2024

Intraarticular Collagen in Patients With Gonarthrosis

An interventional study of Intra-articular infiltration of PVP Collagen and Rehabilitation in Gonarthrosis, sponsored by Instituto Mexicano del Seguro Social. Completed at 1 site in Mexico. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Instituto Mexicano del Seguro Social · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2023, registered Feb 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The objective of this clinical trial is to verify the effectiveness of polyvinyl pyrrolidone collagen in all patients with symptomatic gonarthrosis grades II-IV in patients over 40 years of age. The main objectives that this study aims to answer are the following:

    • Document the effectiveness of intra-articular polyvinylpyrrolidone collagen in the treatment of symptomatic gonarthrosis.
    • Compare the intensity of pain, the degree of stiffness and functionality of the joint, prior to application and one month after the therapeutic intervention.
    • Identify demographic, clinical and therapeutic factors that influence the effectiveness of intra-articular PVP collagen in the treatment of symptomatic gonarthrosis.

Patients diagnosed with symptomatic gonarthrosis Grade II-IV, referred to the Physical Medicine and Rehabilitation service within 3 months, will be selected. Two study groups will be assigned: GROUP those who received intra-articular infiltration of PVP Collagen, GROUP B: patients who received conservative treatment. Through rehabilitation with a home program for one month, in both cases, ENA and the WOMAC scale will be evaluated at the beginning of the study and after 4 weeks.

Read the detailed description

INTRODUCTION: Osteoarthritis is a disorder characterized by progressive deterioration of cartilage in synovial joints, affecting more than 55% of the elderly population, causing significant physical disability, implying a great challenge in medical treatment.

MATERIAL AND METHODS: A sequential, simple randomized clinical trial was carried out in patients diagnosed with symptomatic gonarthrosis Grade II-IV, referred to the Physical Medicine and Rehabilitation service in 3 months, through two study groups: GROUP Those who received intra-articular infiltration of Collagen PVP, GROUP B: patients who received conservative treatment through rehabilitation with a home program for one month. In both cases, ENA and the WOMAC scale were evaluated at the beginning of the study and at 4 weeks.

02

Conditions studied

  • Gonarthrosis

Keywords

  • Gonarthrosis
  • Collagen
  • Infiltration
03

In context

Osteoarthritis, Knee

3,302 studies on the registry are indexed under Osteoarthritis, Knee; 608 are open to participants now.

This study's enrollment of 130 is above the median of 70 across 2,731 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Instituto Mexicano del Seguro Social is the lead sponsor of 124 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age over 40 years.
  2. Both sexes.
  3. Joint stiffness less than 30 minutes.
  4. Crepitus in the knee joint.
  5. Pain in one or both knees lasting more than three months.
  6. Continuous pain Quantified in >5 Analog Numerical Scale.
  7. Patients entitled to the Mexican Social Security Institute.
  8. Radiological criteria for gonarthrosis in phases II, III, IV.
  9. Patients not candidates for surgical treatment.

Exclusion criteria

Exclusion Criteria:

  1. Rheumatoid arthritis, gout or chondrocalcinosis.
  2. Treatment with glucosamine, chondroitin, diacerein, silver non-saponifiables or slow-acting drug in the last three months.
  1. Anticoagulant treatment. 5. Paget's disease. 6. Treatment with viscosupplementation in the last six months. 7. Patients not entitled to the Mexican Social Security Institute.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    GROUP A

    Patients who received intra-articular infiltration of PVP Collagen

    Other: Intra-articular infiltration of PVP Collagen

  • Active comparator
    GROUP B

    Patients who received conservative treatment through rehabilitation with a home program for one month

    Other: Rehabilitation

Interventions

  • OtherIntra-articular infiltration of PVP Collagen

    Intra-articular collagen injection plus physiotherapy program

    Also known as: PVP Collagen

  • OtherRehabilitation

    Patients who received conservative treatment through rehabilitation with a home program for one month

06

What researchers measure

Primary outcomes

  1. Western Ontario and McMaster Universities Osteoarthritis Index - Pain

    number of patients with none, little, quite a bit, a lot, very much

    Time frame: One to three months

  2. Western Ontario and McMaster Universities Osteoarthritis Index - stiffness

    number of patientes with none, little, quite a bit, a lot, very much

    Time frame: One to Three months

  3. Western Ontario and McMaster Universities Osteoarthritis Index - functionality

    number of patients with none, little, quite a bit, a lot, very much

    Time frame: One to three months

  4. Number Analog Scale for pain

    number of patients with 0 (none), 1-2 (very mild pain), 3-4 (mild pain), 5-6 (moderate pain), 7-9 (severe non-disabling pain), 10 (worts pain of life, disabling pain)

    Time frame: one to three months

07

Study locations

1 site
  • Hospital General Regional No. 1 Lic. Ignacio García Téllez
    Mérida, Yucatán 97155, Mexico
08

References and documents

Publications

  • (1) C. Montoya y Verdugo, Evolución Clínica de los Pacientes con Gonartosis Tratados Mediante la Aplicación de Colágeno de Polivinilpirrolidona, Orthotips Vol. 8 No 2, 2012.
  • (2) M.C. Magaña y Villa, Et Al, Uso de colágeno Polimerizado Tipo I, en el Tratamiento de la Gonartrosis Tipo I, Experiencia en el IMSS, Orthotips. Vol. 8 No 2, 2012.
  • (5) John Richmond, David Hunter et al. Treatment of Osteoarthritis of the Knee, Clinical Practice Guidelines Summary, Journal of the American of Orthopedic Surgeons, 591-600. 2009.
  • (8) Bermúdez Hickey R. Et Al; Tratamiento de la pseudoartrosis de tibia con colágeno polivinilpirrolidona; Rev Mex Ortop Traum 1999; 13(2): 148-151.
  • (9) Campell, C.S. Cirugía Ortopédica. Madrid: Harcourt Brace.
  • (11) Alvarez-López A, Fuentes-Véjar R, Soto-Carrasco SR, Nguyen-Pham T, García-Lorenzo Y de la C, Alvarez-López A, et al. Cartílago y gonartrosis. Revista Archivo Médico de Camagüey [Internet]. 2019 Dec 1;23(6):802-13.
  • (13) Mary O Connor. Sex Difference in Osteoarthritis if the Knee a Hip. Journal of the American of Orthopedic Surgeons, 15; 522-525. 2007.
  • (15) Insall, J.N. Rodilla. New York: Mc. Graw Hill.
  • (16) Salazar-Guzmán I, Garfias- Rosas J, Butze-Rangel W. Mejoria clinica y de la calidad de vida a la aplicación de hialino GF-20 y colageno PVP en pacientes con artrosis de rodilla. Rev Esp Med Quir, 2017;22(1):14-21
  • (20) Laboratorios Aspid S.A. de C.V. Fibroquel® DOF.
  • (22) GPC IMSS-329-10 Evidencias y Recomendaciones. Tratamiento Alternativo en Pacientes con Osteoartrosis de Rodilla Grado I-II
  • (23) M.C. Magaña y Villa, Et Al, Uso de colágeno Polimerizado Tipo I, en el Tratamiento no quirugico de la gonartrosis. Experiencia en el IMSS, Orthotips. Vol. 8 No 2, 2012.
  • Borja-Flores A, Macias-Hernandez SI, Hernandez-Molina G, Perez-Ortiz A, Reyes-Martinez E, Belzazar-Castillo de la Torre J, Avila-Jimenez L, Vazquez-Bello MC, Leon-Mazon MA, Furuzawa-Carballeda J, Torres-Villalobos G, Romero-Hernandez F, Albavera-Hernandez C, Perez-Correa J, Castro-Rocha HA. Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study. Adv Orthop. 2020 Jul 22;2020:9398274. doi: 10.1155/2020/9398274. eCollection 2020. PubMed 32802520 ↗
  • Jang S, Lee K, Ju JH. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. Int J Mol Sci. 2021 Mar 5;22(5):2619. doi: 10.3390/ijms22052619. PubMed 33807695 ↗
  • Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000 Sep-Oct;8(5):277-84. doi: 10.5435/00124635-200009000-00001. PubMed 11029555 ↗
  • Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021 Feb 9;325(6):568-578. doi: 10.1001/jama.2020.22171. PubMed 33560326 ↗
  • Furuzawa-Carballeda J, Rodriquez-Calderon R, Diaz de Leon L, Alcocer-Varela J. Mediators of inflammation are down-regulated while apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized collagen. Clin Exp Immunol. 2002 Oct;130(1):140-9. doi: 10.1046/j.1365-2249.2002.01955.x. Erratum In: Clin Exp Immunol 2002 Dec;130(3):565-6. PubMed 12296865 ↗
  • Alvarez-Lopez CA, Garcia-Lorenzo YC. [Relationship between angular deformity and primary osteoarthritis of the knee. Review article]. Acta Ortop Mex. 2015 Jul-Aug;29(4):232-6. Spanish. PubMed 27187002 ↗
  • Salvatori-Rubi J, Montiel-Jarquin AJ, Lopez-Cazares G, Barragan-Hervella R, Ortiz-Arellano R, Garcia-Carrasco M, Mendoza-Pinto C. [Total knee replacement due to grade IV gonarthrosis]. Acta Ortop Mex. 2014 May-Jun;28(3):193-6. Spanish. PubMed 26021117 ↗
  • Furuzawa-Carballeda J, Rojas E, Valverde M, Castillo I, Diaz de Leon L, Krotzsch E. Cellular and humoral responses to collagen-polyvinylpyrrolidone administered during short and long periods in humans. Can J Physiol Pharmacol. 2003 Nov;81(11):1029-35. doi: 10.1139/y03-101. PubMed 14719037 ↗
  • Furuzawa-Carballeda J, Munoz-Chable OA, Macias-Hernandez SI, Agualimpia-Janning A. Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study. Eur J Clin Invest. 2009 Jul;39(7):598-606. doi: 10.1111/j.1365-2362.2009.02144.x. Epub 2009 Apr 23. PubMed 19397687 ↗
  • Furuzawa-Carballeda J, Munoz-Chable OA, Barrios-Payan J, Hernandez-Pando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. Eur J Clin Invest. 2009 Jul;39(7):591-7. doi: 10.1111/j.1365-2362.2009.02154.x. PubMed 19453649 ↗
  • Furuzawa-Carballeda J, Lima G, Llorente L, Nunez-Alvarez C, Ruiz-Ordaz BH, Echevarria-Zuno S, Hernandez-Cuevas V. Polymerized-type I collagen downregulates inflammation and improves clinical outcomes in patients with symptomatic knee osteoarthritis following arthroscopic lavage: a randomized, double-blind, and placebo-controlled clinical trial. ScientificWorldJournal. 2012;2012:342854. doi: 10.1100/2012/342854. Epub 2012 Apr 1. PubMed 22545014 ↗
  • Burbano-Levy X, Qf DC, Act EP, Alba IR, Qf LZ. Costo Utilidad de Colagena Polivinil-Pirrolidona en el Tratamiento de Osteartrosis de Rodilla en Mexico. Value Health Reg Issues. 2014 Dec;5:40-47. doi: 10.1016/j.vhri.2014.06.006. Epub 2014 Aug 30. PubMed 29702786 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06275880
Lead sponsor
Instituto Mexicano del Seguro Social
Responsible party
Roberto Carlos Pech Arguelles (Clinical Professor, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Feb 23, 2024
Start date
Apr 1, 2023
Primary completion
Jul 30, 2023
Completion
Jan 10, 2024
Last update
Feb 23, 2024

Study contacts

Abigail Mariela Arriaga Coria, Physician
principal investigator · Instituto Mexicano del Seguro Social
Raúl Morales Reyes, Physician
study chair · Instituto Mexicano del Seguro Social

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion